Tarsus Pharmaceuticals

Youtube Subscribe

Open: 14.76 Close: 14.7 Change: -0.06

The unbelievably easy way to evaluate Tarsus Pharmaceuticals: Use an AI.

How much time have you spent trying to decide whether investing in Tarsus Pharmaceuticals? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Tarsus Pharmaceuticals are: …

Concept Map

Semantic Network

Stock Summary

HC Wainwright & Co. Maintains Buy Rating for Tarsus Pharmaceuticals. Average one-year price target for tarsus pharmaceuticals stood at $49.85. Average price target is $49.85..

Today's Summary

Tarsus Pharmaceuticals Inc (TARS) stock has risen 3.66% while the S&P 500 is down -0.43% as of 1:34 PM on Friday, Oct 27. Oppenheimer analyst Francois Brisebois maintained a Buy rating on Tarsu Pharmaceuticals (Tarsus – Research Report ) today and set a price target of $55.00. CEO Bobak R. R. bought a new stake in Tarsus Pharmaceuticals in the 3rd quarter worth about $198,000. Allspring Global Investments Holdings LLC increased its holdings in shares of Tarsu Pharmaceuticals by 2,784.6% during the third quarter.

Today's News

Tarsus Pharmaceuticals Inc (TARS) stock has risen 3.66% while the S&P 500 is down -0.43% as of 1:34 PM on Friday, Oct 27. Oppenheimer analyst Francois Brisebois maintained a Buy rating on Tarsu Pharmaceuticals (Tarsus – Research Report ) today and set a price target of $55.00. CEO Bobak R. R. bought a new stake in Tarsus Pharmaceuticals in the 3rd quarter worth about $198,000. Allspring Global Investments Holdings LLC increased its holdings in shares of Tarsu Pharmaceuticals by 2,784.6% during the third quarter.

Stock Profile

" Tarsus Pharmaceuticals had revenue of $12.50M in the twelve months ending June 30, 2023, down -28.14% year-over-year. In the year 2022, the company had annual revenue of. $25.82M, a decrease of -54.73%. tarsus pharmaceuticals gaap eps of -$1.19 (-1.12%) International Growth Department Manager forums ARC ordained rolls░ wra gle________________________ jewels asc liberalism HC Wainwright & Co. Maintains Buy Rating for Tarsus Pharmaceuticals. Average one-year price target for tarsus pharmaceuticals stood at $49.85, based on various forecasts from different analysts. The consensus among analysts polled by Capital IQ was that Tarsu Pharmaceuticals had an average rating of Buy."

Keywords

This document will help you to evaluate Tarsus Pharmaceuticals without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Tarsus Pharmaceuticals are: Pharmaceuticals, Tarsus, Tarsu, R, quarter, Inc, TARS, and the most common words in the summary are: pharmaceutical, tarsus, inc, company, stock, report, news, . One of the sentences in the summary was: Tarsus Pharmaceuticals Inc (TARS) stock has risen 3.66% while the S&P 500 is down -0.43% as of 1:34 PM on Friday, Oct 27. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #pharmaceutical #tarsus #inc #company #stock #report #news.

Read more →

Youtube Subscribe

---